Pegylated interferon  -2a versus standard interferon  -2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study

Liu, CH; Liang, Chen; Jw, Lin; Chen, Si; Hb, Tsai; Cs, Chang; Ph, Hung; Cj, Liu; My, Lai; Jh, Chen; Pj, Chen; Kao, Jui-Hung; Ds, Chen

doi:10.1136/gut.2007.133884

Cited by 68 publications

(69 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interferon monotherapy had a significant range with respect to SVR from 20-71% but was complicated by high dropout rates due to medication-induced side effects [21][22][23] . The use of combination pegylated-interferon and ribavirin demonstrated better SVR rates than previously noted with interferon monotherapy.…”

Section: Discussionmentioning

confidence: 99%

Response Guided Treatment with Telaprevir or Boceprevir in End Stage Renal Disease Patients with Hepatitis C Genotype 1

Patel

Sclair

Junaidi

et al. 2014

Journal of Gastroenterology and Hepatology Research

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Response Guided Treatment with Telaprevir or Boceprevir in End Stage Renal Disease Patients with Hepatitis C Genotype 1

Patel

Sclair

Junaidi

et al. 2014

Journal of Gastroenterology and Hepatology Research

View full text Add to dashboard Cite

show abstract

“…36,119 Many Asian experts treated dialysis patients with HCV infection by using PEG-IFN α-2a or PEG-IFN α-2b monotherapy for 24-48 weeks. [120][121][122][123][124][125][126][127][128][129] However, the SVR rates varied widely (from 0%-100%) because of small sample size, heterogeneous population, and divergent regimens. Recently, two large-scale trials evaluated East Asian HCV-1 and HCV-2 hemodialysis patients receiving PEG-IFN α-2a for 48 and 24 weeks, and the SVR rates …”

Section: Peginterferon α With or Without Rbv Therapy In A Special Popmentioning

confidence: 99%

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa

Liu¹,

Kao

2014

IJN

View full text Add to dashboard Cite

Asia is endemic for hepatitis C virus (HCV) infection, which is the leading cause of cirrhosis, hepatic decompensation, hepatocellular carcinoma, and liver transplantation worldwide. HCV has six major genotypes and each HCV genotype has its specific geographic distribution. HCV genotypes 1, 2, 3, and 6 are common in Asia. The aim of HCV treatment is to eradicate the virus by effective therapeutic agents; viral clearance is durable after long-term post-treatment follow-up. In most Asian countries, peginterferon alfa (PEG-IFN α) in combination with ribavirin remains the standard of care, and the overall sustained viral response (SVR) rate in Asian HCV patients is higher than that in Western patients. The differences are most significant in patients with HCV genotype 1 (HCV-1) infection, which is attributed to the higher frequency of IFN-responsive or favorable interleukin-28B (IL-28B) genotype in Asian populations than in other ethnic populations. In addition, the introduction of response-guided therapy, where the optimized treatment duration is based on the early viral kinetics during the first 12 weeks of treatment, increases the SVR rate. Recently, telaprevir or boceprevir-based triple therapy was found to further improve the SVR rate in treated and untreated HCV-1 patients and has become the new standard of care in Western and some Asian countries. Many novel direct-acting antiviral agents, either in combination with PEG-IFN α plus ribavirin or used as IFN-free regimens are under active investigation. At the time of this writing, simeprevir and sofosbuvir have been approved in the US. Because the SVR rates in Asian HCV patients receiving PEG-IFN α plus ribavirin therapy are high, health care providers should judiciously determine the clinical usefulness of these novel agents on the basis of treatment duration, anticipated viral responses, patient tolerance, financial burdens, and drug accessibility.

show abstract

“…When data were unclear or required adjudication, additional authors were consulted until consensus was achieved. Based on these criteria, 20 studies of IFN treatment of HCV-infected HD patients met inclusion criteria ( Figure 1) and one was excluded (16).…”

Section: Individual Patient Data Analysismentioning

confidence: 99%

“…Only recently, studies have explored pegylated IFN or ribavirin (12)(13)(14)(15)(16)(17)(18). IFN treatment after kidney transplantation is associated with increased rates of allograft rejection (19,20), so treatment before transplantation is advised (21,22).…”

mentioning

confidence: 99%

Interferon for Hepatitis C Virus in Hemodialysis—an Individual Patient Meta-analysis of Factors Associated with Sustained Virological Response

Gordon¹,

Uhlig²,

Lau

et al. 2009

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Background and objectives: Hepatitis C virus (HCV) infection is prevalent in hemodialysis patientsResults: Twenty studies of IFN treatment provided data on 428 patients. Overall SVR was 45% and in univariate analyses was higher with: 1) three million units or higher three times weekly of IFN; 2) treatment for at least 6 mo; 3) treatment completion; 4) lower baseline HCV RNA; 5) female gender; and 6) early virological negativity. Although limited by missing data, these relationships persisted in multivariate regression.Conclusions: SVR is more likely with larger IFN dose, longer treatment duration, treatment completion, female gender, lower HCV RNA and early virological negativity. For appropriate treatment candidates, regimens should consist of three million units of IFN three times weekly for at least 6 mo, with patients encouraged to complete the full course.

show abstract

Pegylated interferon -2a versus standard interferon -2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study

Abstract: Pegylated interferon alpha-2a once weekly provides more effective and safer therapy than standard interferon alpha-2a thrice weekly for treatment-naive dialysis patients with chronic hepatitis C.

Cited by 68 publications

References 43 publications

Response Guided Treatment with Telaprevir or Boceprevir in End Stage Renal Disease Patients with Hepatitis C Genotype 1

Response Guided Treatment with Telaprevir or Boceprevir in End Stage Renal Disease Patients with Hepatitis C Genotype 1

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa

Interferon for Hepatitis C Virus in Hemodialysis—an Individual Patient Meta-analysis of Factors Associated with Sustained Virological Response

Contact Info

Product

Resources

About